TRACON Pharmaceuticals

TRACON Pharmaceuticals, Inc. engages in the development and commercialization of targeted therapies for cancer, and ophthalmic and fibrotic diseases. Its products include TRC105, an anti-endoglin antibody for the treatment of solid tumor types, TRC205 created for the treatment of fibrotic diseases, and TRC102, a small molecule that is in clinical development made for lung cancer and glioblastoma. The company was founded in October 2004 and is headquartered in San Diego, CA.

Earnings data Q1 2023

Earnings data Q2 2023

Tracon (TCON) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Tracon (TCON) Moves to Buy: Rationale Behind the Upgrade

TRACON Pharmaceuticals, Inc. (NASDAQ:TCON ) Q4 2022 Earnings Conference Call March 8, 2023 4:30 PM ET Company Participants Charles Theuer - CEO, President & Director Scott Brown - CFO Conference Call Participants Soumit Roy - Jones Research Joel Beatty - Robert W. Baird & Co. Robert Hazlett - BTIG Operator Good day, ladies and gentlemen, and welcome to TRACON Pharmaceuticals Fourth Quarter and Year Ended 2022 Earnings Conference Call.

TRACON Pharmaceuticals, Inc. (TCON) Q4 2022 Earnings Call Transcript

SAN DIEGO, March 08, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, today announced financial results for the fourth quarter and year ended December 31, 2022. The Company will host a conference call and webcast today at 4:30 PM Eastern Time / 1:30 PM Pacific Time.

TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update

SAN DIEGO, Feb. 28, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, announced today that it will report its fourth quarter and year-end 2022 financial and operating results after the close of U.S. financial markets on Wednesday, March 8, 2023. In addition, management will host a conference call to provide an update on corporate activities and discuss the financial results.

TRACON to Report Fourth Quarter and Year-End 2022 Financial Results and Provide Corporate Update on March 8, 2023

Checkpoint Therapeutics

OmniAb Inc

Performant Financial

ProQR Therapeutics

Analysts Say These Are Penny Stocks To Buy But Are They Worth The Risk? The post 5 Penny Stocks With Explosive Price Targets & Buy Ratings From Analysts appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

5 Penny Stocks With Explosive Price Targets & Buy Ratings From Analysts

Initial $3.5M Funding Maintains Cash Runway of Mid-2023 Initial $3.5M Funding Maintains Cash Runway of Mid-2023

TRACON Pharmaceuticals Announces up to $30M Non-Recourse Non-Dilutive Financing Related to Arbitration Award Decision Expected in Q1 2023

TRACON Pharmaceuticals Inc (NASDAQ:TCON) revealed that its PD-L1 antibody envafolimab achieved positive results based on the double-digit Objective Response Rate (ORR) assessed by a blinded independent central review in its ongoing multicenter ENVASARC Phase 2 pivotal trial in patients with Undifferentiated Pleomorphic Sarcoma (UPS) or Myxofibrosarcoma (MFS) cancers. According to TRACON, the independent data monitoring committee (IDMC) for the ongoing ENVASARC Phase 2 pivotal trial recommended "continued accrual as planned in both cohorts: single agent envafolimab and envafolimab in combination with Yervoy (ipilimumab).

TRACON achieves positive results based on Double-Digit Objective Response Rate in each cohort from ENVASARC Phase 2 Pivotal Trial

Objective Response Rate (ORR) by Central Review Achieved in Each Cohort at Interim Efficacy Analysis that Exceeded the Futility Threshold

TRACON Pharmaceuticals Announces Positive Results Based on Double-Digit Objective Response Rate in Each Cohort from the Ongoing ENVASARC Phase 2 Pivotal Trial

Today, we look back in on clinical stage developmental firm TRACON Pharmaceuticals for the first time since early 2021. The company's primary drug candidate Envafolimab could provide certain advantages over other approved PD-L1 inhibitors.

Revisiting Tracon Pharmaceuticals

TRACON Pharmaceuticals Inc (NASDAQ:TCON) said it has dosed the first patient in a Phase 1/2 trial evaluating the company's CTLA-4 antibody, YH001, in combination with its PD-L1 antibody envafolimab and with doxorubicin, in front line therapy of patients with malignant tumours. The Phase 1/2 trial will assess the safety and efficacy of the triplet combination of YH001, envafolimab and doxorubicin in the common sarcoma sub-types of leiomyosarcoma and dedifferentiated liposarcoma, according to TRACON.

TRACON Pharmaceuticals doses first patient in drug trial to treat malignant tumours

SAN DIEGO, Nov. 21, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, today announced dosing of the first patient in a Phase 1/2 trial evaluating the Company's CTLA-4 antibody, YH001, in combination with its PD-L1 antibody envafolimab and with doxorubicin in front line therapy in patients with sarcoma (NCT 05448820).

TRACON Pharmaceuticals Announces Dosing of First Patient in Phase 1/2 Trial of YH001 in Combination with Envafolimab and Doxorubicin in Front Line Sarcoma

TRACON Pharmaceuticals, Inc. (NASDAQ:TCON ) Q3 2022 Earnings Conference Call November 14, 2022 4:30 PM ET Company Participants Charles Theuer - CEO, President & Director Scott Brown - CFO Conference Call Participants Joel Beatty - Robert W. Baird & Co. Edward White - H.C.

TRACON Pharmaceuticals, Inc. (TCON) Q3 2022 Earnings Call Transcript

TRACON Pharmaceuticals Inc announced that it has ended its third-quarter 2022 with cash and equivalents of $17.0 million as of September 30, 2022, which the company says is expected to fund its operations into mid-2023. The clinical stage biopharmaceutical company also noted that its net loss for the quarter narrowed to $6.4 million from $7.0 million a year earlier, as it reduced its general and administrative expenses for the period to $2.3 million, compared to $4.2 million in 3Q 2021.

TRACON Pharmaceuticals ends 3Q with $17M cash and equivalents to fund operations into mid-2023

SAN DIEGO, Nov. 14, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, today announced financial results for the third quarter ended September 30, 2022. The Company will host a conference call and webcast today at 4:30 PM Eastern Time / 1:30 PM Pacific Time.

TRACON Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

TRACON Pharmaceuticals Inc has received a recommendation from the Independent Data Monitoring Committee that its ENVASARC Phase 2 pivotal trial can proceed as planned, the company announced. The committee made its recommendation following a review of 12-week safety data from patients enrolled in the trial as of June 30.

TRACON Pharmaceuticals says ENVASARC trial gets recommendation from review committee to proceed as planned

Review of Interim Efficacy Data by IDMC to Occur in Fourth Quarter Review of Interim Efficacy Data by IDMC to Occur in Fourth Quarter

TRACON Pharmaceuticals Announces Results of Independent Data Monitoring Committee Review of 12 Week Safety Data from ENVASARC Phase 2 Pivotal Trial - Trial to Proceed as Planned

Lazydays

Protara Therapeutics Inc

Mountain Crest Acquisition Corp II

L. B. Foster

LINKBANCORP Inc

Liquidia Technologies Inc

Larimar Therapeutics Inc

Macerich

MFA Financial

B. Riley Financial

TransCode Therapeutics

Tilly's

Zivo Bioscience

In October 2021, I made a big call on Longeveron (NASDAQ: LGVN ) stock, a biotech firm working on a promising Alzheimer's therapy.

Insider Buying 2022: 15 Stocks to Bet On Despite the Bear Market

TRACON Pharmaceuticals Inc (NASDAQ:TCON) announced that its undifferentiated pleomorphic sarcoma (UPS) drug envafolimab has been granted fast track designation by the US Food and Drug Administration. The designation covers the development of envafolimab for patients with locally advanced, unresectable or metastatic UPS and myxofibrosarcoma (MFS) who have progressed on one or two prior lines of chemotherapy.

TRACON Pharmaceuticals earns FDA fast track designation for sarcoma drug envafolimab

SAN DIEGO, Sept. 14, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, announced today that the U.S. Food and Drug Administration (FDA) has granted fast track designation for the development of envafolimab (KN035) for patients with locally advanced, unresectable or metastatic undifferentiated pleomorphic sarcoma (UPS) and myxofibrosarcoma (MFS) who have progressed on one or two prior lines of chemotherapy.

TRACON Pharmaceuticals Announces Fast Track Designation by the FDA for Envafolimab for the Treatment of the Soft Tissue Sarcoma Subtypes of UPS and MFS

TRACON Pharmaceuticals Inc (NASDAQ:TCON) has announced a $35 million non-dilutive long-term debt facility with Runway Growth Capital LLC to support its ongoing pivotal ENVASARC trial to treat cancer and for general corporate purposes. The biopharma said that $10 million of the $35 million loan was funded upon closing, and the additional $25 million available may be funded upon achieving "certain clinical milestones and at Runway's discretion".

TRACON Pharmaceuticals strikes $35M debt financing facility with Runway Growth Capital

Initial $10 million draw extends cash runway to mid-2023 Initial $10 million draw extends cash runway to mid-2023

TRACON Pharmaceuticals Announces $35 Million Non-Dilutive Debt Financing with Runway Growth Capital

BEIJING & SAN DIEGO--(BUSINESS WIRE)-- #Biocytogen--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen") and TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), today jointly announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for the initiation of a Phase 1/2 clinical study of YH001 in combination with envafolimab and doxorubicin for the treatment of sarcoma patients, including patients who have not received prior therapy. The Phase 1/2 tr

US FDA Approval of IND for CTLA-4 Antibody YH001 for the Treatment of Front-line Sarcoma Patients in Combination with Envafolimab

TRACON Pharmaceuticals Inc (NASDAQ:TCON) said the US Food and Drug Administration (FDA) has approved its Investigational New Drug application for the initiation of a phase one-two clinical trial of YH001 in combination with envafolimab and doxorubicin for the treatment of sarcoma, including in patients who have not received prior therapy. The trial will assess the safety and efficacy of YH001 and envafolimab in patients with the rare sarcoma subtypes of alveolar soft part sarcoma and chondrosarcoma.

TRACON Pharmaceuticals announces FDA approval for CTLA-4 antibody YH001 for treating sarcoma in combination with envafolimab

SAN DIEGO, Aug. 29, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, today announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for the initiation of a Phase 1/2 clinical trial of YH001 in combination with envafolimab and doxorubicin for the treatment of sarcoma patients, including patients who have not received prior therapy.

TRACON Pharmaceuticals Announces Approval of IND for CTLA-4 Antibody YH001 for the Treatment of Front-line Sarcoma Patients in Combination with Envafolimab

TRACON Pharmaceuticals, Inc. (NASDAQ:TCON ) Q2 2022 Earnings Conference Call August 10, 2022 4:30 PM ET Company Participants Charles Theuer - President and Chief Executive Officer Scott Brown - Chief Financial Officer Conference Call Participants Maury Raycroft - Jefferies Ed White - H.C. Wainwright Soumit Roy - Jones Research Nick Abbott - Wells Fargo Joel Beatty - Baird Operator Good day, ladies and gentlemen, and welcome to TRACON Pharmaceuticals Second Quarter 2022 Earnings Conference Call.

News for TRACON Pharmaceuticals Stock (TCON)